The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.

摘要: Non-muscle invasive bladder cancers (NMI-BCs) represent 75% of upon presentation. After removal the primary tumour by transurethral resection, multiple recurrences continue to develop in 70% patients. Consequently, prolonged and costly surveillance cystoscopy is required. Mutations FGFR3 oncogene are common NMI-BCs associated with a lower chance progression muscle-invasive disease. Here we analysed consistency mutations recurrent tumours. This knowledge crucial importance if mutation analysis on urinary cells be used as an alternative for cystoscopical surveillance. To this end, monitored disease process status tumours 118 patients NMI-BC. During median follow-up 8.8 years, these underwent 2133 cystoscopies 80 developed 414 recurrences. were equally prevalent (63%). Patients can have different types Recurrence risk was not significantly mutant or wild-type tumour. rates varied widely between but constant patient unrelated status. In group, contrast continued after 10 years. 81% tumour, found. Moreover, group stage grade than those (p < 0.001). These results suggest that voided urine combination reduced frequency presenting worth investigating.